Motus GI Holdings Inc (NASDAQ:MOTS) – Stock analysts at Oppenheimer issued their Q1 2018 earnings per share estimates for shares of Motus GI in a research report issued to clients and investors on Monday. Oppenheimer analyst S. Lichtman forecasts that the company will post earnings per share of ($0.24) for the quarter. Oppenheimer currently has a “Outperform” rating and a $7.00 target price on the stock. Oppenheimer also issued estimates for Motus GI’s Q2 2018 earnings at ($0.30) EPS, Q3 2018 earnings at ($0.19) EPS, Q4 2018 earnings at ($0.20) EPS, FY2018 earnings at ($0.93) EPS, FY2019 earnings at ($0.96) EPS, FY2020 earnings at ($0.83) EPS and FY2021 earnings at ($0.40) EPS.
Separately, Piper Jaffray Companies started coverage on Motus GI in a report on Sunday. They set an “overweight” rating and a $7.00 price target on the stock.
In other Motus GI news, CEO Mark Pomeranz acquired 8,000 shares of the business’s stock in a transaction that occurred on Friday, February 16th. The stock was purchased at an average cost of $5.00 per share, with a total value of $40,000.00. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, major shareholder Life Sciences Maste Perceptive acquired 1,000,000 shares of the business’s stock in a transaction that occurred on Friday, February 16th. The shares were acquired at an average cost of $5.00 per share, with a total value of $5,000,000.00. The disclosure for this purchase can be found here. Insiders have purchased a total of 1,175,000 shares of company stock valued at $5,875,000 over the last three months.
About Motus GI
Motus GI Holdings, Inc is a medical technology company. The Company is developing Pure-Vu system that integrates with existing colonoscopes to cleanse poorly prepped colons during the colonoscopy procedure. The Pure-Vu system uses a precise mixture of water and air to loosen debris from the colon mucosa while simultaneously evacuating the bowel contents, clearing the way for the endoscopist to perform a high quality examination, even when the patient is not fully clean prior to their procedure.
Receive News & Ratings for Motus GI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Motus GI and related companies with MarketBeat.com's FREE daily email newsletter.